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Executive Summary
Antimicrobial resistant organisms are a growing threat in the United States and globally.
It has become the expectation that healthcare institutions, including hospitals, contribute
resources to create and maintain antimicrobial stewardship programs to decrease antimicrobial
resistance, improve patient outcomes, and decrease the spread of multi-drug resistant organisms.
The methods utilized to evaluate antimicrobial stewardship at hospitals often only evaluate
outcome measures and fail to capture knowledge of the hospital antimicrobial stewardship
program among prescribers, clinical pharmacists, and nurses, as well potential barriers to
antimicrobial stewardship among healthcare providers. The purpose of this Doctor of Nursing
project is to implement and evaluate the use of tracer methodology to evaluate both
implementation and outcomes of a hospital antimicrobial stewardship program. For this project,
a tracer was designed by a multidisciplinary team to evaluate treatment of community acquired
pneumonia at a local 130-bed regional trauma center affiliated with a large regional not-forprofit health system. The hospital was motivated to conduct the evaluation in response to a
suggestion from a state government agency active in promoting hospital ASPs. The results of
this evaluation suggest that successful implementation of a tracer is reliant on the quality of
questions, the abilities of the surveyor, response from participants, and recognition that
antimicrobial stewardship is multifaceted. Further, the interpretation of tracer questions is not
always straightforward and tracer results should be interpreted as such. When possible, tracer
questions should be specific enough to produce results that are detailed and actionable.
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Utilizing Tracer Methodology to Evaluate the Effectiveness of a Hospital Antimicrobial
Stewardship Program
Introduction
Antimicrobial resistance of microorganisms, including bacteria and fungi, is a growing
threat globally and in the United States (Centers for Disease Control [CDC], 2020; World Health
Organization [WHO], 2018). In 2013 the CDC estimated at least 23,000 people die each year
from antibiotic-resistant infections and more than two million people are infected with antibioticresistant organisms (CDC, 2013). The data released by the CDC in 2013 held the caveat that the
available numbers were likely underestimated due to limitations in data collection (CDC, 2013).
The CDC revised the estimates from 2013 using updated methodologies and data resources and
these revised estimates indicated that when the 2013 report was published, more than 2.6 million
antibiotic-resistant infections and 44,000 deaths occurred (CDC, 2019a). The most recent data
released in 2019 reports more than 2.8 million antibiotic-resistant infections occur each year in
the United States and more than 35,000 people die from such infections (CDC, 2019a). However,
when comparing the newly recalculated data from 2013 to the newest available data in 2019, the
CDC found that deaths from antibiotic-resistant infections had decreased by 18 percent thanks to
actions implemented through the National Action Plan for Combating Antibiotic-Resistant
Bacteria (CARB) (CDC, 2019a). A decrease in deaths is encouraging, however, antibiotic
resistance remains a threat due to the ability of microorganisms to constantly adapt and develop
mechanisms of resistance to antibiotics (WHO, 2018).
The development of resistance to antibiotics by microorganisms is evolutionarily
inevitable, however, when antibiotics are frequently present in the environment or a host, the
development of resistance is accelerated (CDC, 2020; WHO 2018). Inappropriate use of
antibiotics includes administration of antibiotics that are not necessary, not the optimal antibiotic,
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or the incorrect dose and duration of an antibiotic (CDC, 2019b). The CDC has concluded that
20-50% of antibiotics prescribed in acute care hospitals are unnecessary or inappropriate.
Furthermore, researchers at the CDC found that the rate at which healthcare providers prescribe
antibiotics varies widely among hospitals, with some providers prescribing three times as many
antibiotics when compared to providers in similar departments of other hospitals (CDC, 2019c).
Also of note, Baggs, Fridkin, and Pollack (2016) found that while the overall rate of antibiotic
use in hospitals did not change from 2006 to 2012, changes were noted in the types of antibiotics
being prescribed. The researchers found that the use of carbapenems increased by 37 percent and
the use of vancomycin increased by 32 percent. Thus, decreases in the use of fluroquinolones
and first- and second- generation cephalosporins were offset by the significant increases in
vancomycin and agents with broad-spectrum activity against gram-negative bacteria.
Antimicrobial stewardship programs (ASPs) are coordinated efforts which promote the
appropriate use of antimicrobials within various settings. The goals of ASPs are to improve
patient outcomes, decrease antimicrobial resistance, and decrease the spread of infections caused
by multi-drug resistant organisms (MDROs) (Association for Professionals in Infection Control
and Epidemiology [APIC], n.d.). Hospital-based ASPs have been shown to effectively reduce
inappropriate use of antibiotics, thereby reducing rates of Clostridium difficile, antibiotic
resistance, and side effects related to antibiotics (CDC, 2019c). In 2014 the CDC released the
Core Elements of Hospital Antibiotic Stewardship Programs providing the basis for hospitals to
establish and improve stewardship programs. The seven core elements: (a) Leadership
Commitment, (b) Accountability, (c) Pharmacy Expertise, (d) Action, (e) Tracking, (f)
Reporting, and (g) Education are meant to serve as a framework for hospitals by supplying the
structural and procedural components necessary for a stewardship program. Five years later, the
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CDC has released an updated version of the Core Elements of Hospital Antibiotic Stewardship
Programs that is based on new evidence pertaining to antibiotic stewardship and information
gathered since 2014. The seven core elements remain the same though each includes updates to
incorporate new evidence from the field of antibiotic stewardship and lessons learned from the
past five years. The structure of ASPs remain the decision of each individual hospital or
healthcare system based on the size, type, and available resources, but programs are expected to
integrate components from all seven core elements (CDC, 2019d).
The Joint Commission (TJC) and the Det Norske Veritas-Germanischer Lloyd (DNVGL) use the Core Elements as the basis for accreditation standards (DNV-GL, 2019).
Additionally, the 2019 revision of the hospital conditions of participation from the Centers for
Medicare and Medicaid Services (CMS) created a federal regulation for hospital ASPs and
references the Core Elements (Centers for Medicare and Medicaid Services [CMS], 2019). As of
2018, 85% of acute care hospitals in the United States report implementing all seven CDC Core
Elements (CDC, 2019d). On January 1, 2017 TJC released a new antimicrobial stewardship
standard applicable to hospitals and critical access hospitals (TJC, 2016; TJC, 2017). One
method utilized by TJC to assess compliance with accreditation standards is tracer methodology,
however, such a method has not yet been utilized to assess hospital ASPs. Tracers can provide
organizations with useful feedback by either validating practices or identifying knowledge gaps
or deviations from evidence-based practices and guidelines. This project applied tracer
methodology with the goal of evaluating the success of a hospital ASP, identifying potential gaps
in knowledge or deviations from evidence-based practices, and verifying the fulfillment of
accreditation requirements.
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Problem Description
A 130-bed regional trauma center affiliated with a large regional not-for-profit health
system required evaluation of an active ASP (see Appendix A for Letter of Support from
Agency). Once hospitals implement an ASP, ongoing assessment is necessary to ensure
interventions are effective and to provide hospital leadership and healthcare providers with
feedback. Assessing ASPs provides program leaders with the opportunity to identify potential
gaps or deviations from evidence-based practices and the obstacles related to antibiotic
stewardship healthcare providers encounter. Previous interventions implemented by the hospital
stewardship team included the following: (a) audit and feedback; (b) provision of a hospital
antibiogram to clinicians, (c) educational presentations regarding clinical guidelines and
antibiotic prescribing, (d) encouragement to conduct antibiotic “timeouts”, (e) formulary
restrictions, and (f) implementation of specific diagnostic testing for patients being treated with
specific antibiotics for certain diagnoses.
Tracking and reporting antibiotic prescribing and outcomes such as C. difficile and
resistance patterns provides valuable feedback, however, understanding the ways in which
providers prescribe antibiotics and the factors that influence their actions helps program leaders
to design and modify programs that support providers in their stewardship practices. Past
evaluation methods at the hospital did not attempt to specifically identify processes and barriers
related to antimicrobial prescribing. Determining the feasibility of applying tracer methodology
to evaluate a hospital ASP came to focus when an ASP physician lead proposed the intervention,
and a state government agency proposed using tracer methodology to evaluate hospital ASPs.
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The hospital employs 42 hospitalists on staff who provide care coverage for six different
units during twelve-hour shifts. When patients are admitted through the emergency department
(ED), orders are initiated by the ED physician who provides a handoff report to the internal
medicine hospitalist. The hospitalist reviews the orders placed for the patient and makes changes
as necessary. Each unit of the hospital is assigned a clinical pharmacist during the day who
reviews patient medications. Rounds on select patients are led each morning by the hospitalist
and are attended by the clinical pharmacist, nurses, and case managers. During rounds the status
of the patient is discussed with regards to plan of care, including nursing care, medications, and
preparations necessary for discharge.
The ASP team had nine members: (a) an antimicrobial stewardship physician lead; (b) an
antimicrobial stewardship pharmacist lead; (c) an infectious disease specialist; (d) the
microbiology lab director; (e) the hospital lab director; (f) the pharmacy director; (g) a
hospitalist; (h) and infection preventionist; (i) and an administrator. To evaluate current
prescribing practices and identify potential barriers to antimicrobial stewardship, the
antimicrobial stewardship physician lead team proposed implementing tracer methodology to
specifically evaluate treatment of community acquired pneumonia (CAP) and general knowledge
of antibiotic stewardship among physicians, clinical pharmacists, and nurses.
Available Knowledge
PICOT
With the intent of creating and implementing a tracer to evaluate a hospital ASP and the
impact of the program on the knowledge and practices of staff, a review of the literature was
conducted to search for evidence supporting best practices. A PICOT question guided the search.
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The components of a PICOT question are: patient population, intervention, comparison,
outcome, and time (University of North Carolina, 2019).
Is conducting a tracer in an acute care hospital, from February 2020 to July 2020, an
effective method for evaluating a hospital-based ASP with regards to the treatment of CAP when
compared to only using process measures?
Search Methodology
A systematic review of the literature was conducted in the PUBMED and CINHAL
databases between December 2019 and April 2020. The search criteria included full text, peer
reviewed articles in English from 2010 to 2020 using the following search terms in various
forms: tracer method*, antibiotic, and antimicrobial. The search yielded a total of 454 articles,
including duplicates. Articles were selected if tracer methodology was proposed or implemented
to evaluate a program addressing a clinical need within an acute care or outpatient setting.
Articles were appraised using the John Hopkins Research Evidence Appraisal Tool (see
Appendix B) (Johns Hopkins Hospital, 2017).
Literature Review
ASP evaluation methods. Previous methods utilized to assess ASPs include
interventional, retrospective, and ecological studies to evaluate economic outcomes, clinical
outcomes, microbial and resistance outcomes, and process measures (Aldeyab et al., 2012;
McGregor & Furuno, 2014). Clinical outcomes include hospital length of stay (LOS), mortality,
clinical cure or failure, readmission rates, and adverse events associated with antimicrobial
therapy. Assessing microbial or resistance outcomes involves measuring the incidence or
prevalence of colonization or infection by an organism at the individual or population level.
Process measures data include antimicrobial days of therapy, however, such measures should be
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validated in order to establish an association with clinical outcomes (McGregor & Furuno,
2014). To assess progress and barriers to ASPs, surveys, and questionnaires have been
administered (Van Limburg, Sinha, Lo-Ten-Foe, & Gemert-Pijnen, 2014). In a review of the
literature, Hulscher and Prins (2017) concluded that antimicrobial stewardship teams face the
challenge of selecting change interventions based on assessment of barriers, facilitators, and
determinants of change interventions, especially since large differences in improvement were
noted between studies that tested similar change interventions.
Description of tracers. Three types of tracer methods exist; individual tracers, systems
tracers, and accreditation program-specific tracers (TJC, 2018). Individual tracers examine
patient care experiences while at an organization by evaluating the provision of care and
treatment within an institution. In individual tracers, patients are the framework used to
determine compliance with set standards. Systems tracers aid in evaluating an entire system or
process, including the way related processes are incorporated and the way different departments
and disciplines coordinate and communicate within the system or process. Systems tracers are
used to evaluate data management, infection control, and medication management. Accreditation
program-specific tracers help to identify risks and safety concerns at different levels of care,
treatment, and services, especially regarding issues specific to the organization (TJC, 2018).
When TJC conducts a tracer, it generally involves speaking with multiple staff members,
patients, and family to learn details about each healthcare experience. Surveyors are collecting
information to evaluate compliance with National Patient Safety Goals; adherence to policies and
procedures; staff competency; communication within and between departments, programs, and
services; and the physical environment as it relates to safety. Commonly, tracers start at the point
of sample collection, critical results, transfusions, point of care testing, or frozen sections.
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Surveyors review items such as orders, policies and procedures, employee competency, blood
utilization review, process improvement, patient medical records, and instrument maintenance
records. They also observe staff and conduct staff interviews (Olea, Paiano, & Olson, n.d.).
A search of the literature revealed studies in which tracer methodology was applied to
novel applications, however, the application of tracer methodology to evaluate ASPs was not
among these applications. Tracer methodology has been suggested or applied to assess a variety
of other clinical and patient care practices including surgical site infections, pain reassessment
standards, infection control standards, outpatient mental health services, and end-of-life care
(Bailey et al., 2015; Bookbinder et al., 2015; Padgette & Wood, 2018; Ross, Feider, Nahm, &
Staggers, 2017; Wisdom et al., 2012). Padgette and Wood (2018) recognize tracer methodology
can be adapted and applied to all areas of inpatient and ambulatory healthcare at the individual or
system level. Additionally, Bookbinder et al. (2018) suggest tracer methodology may be adapted
to routine quality improvement activities when implemented in different settings, proposing the
integration of the tracer into the normal work of a unit with a simple audit tool to guide
information gathering.
A mock tracer is a simulation of an actual tracer. Developing a mock tracer requires four
primary steps: planning, conducting, analyzing, and applying (TJC, 2011). To develop and
implement a tracer, TJC recommends a series of steps and methods within the steps. The studies
that utilized tracer methodology all had similar implementation approaches which closely
followed the steps and methods recommended by TJC. An integrative discussion of the literature
review will be discussed according to the steps proposed by TJC.
Planning for tracer methodology. According to TJC (2011) the planning stage involves
establishing a schedule, determining the scope of the tracer, identifying surveyors, and training
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the surveyors. Padgette and Wood (2018) highlight the importance of involving a
multidisciplinary team in the planning phase as each member can offer insight and has an interest
in the practice being traced. For example, to plan for a tracer evaluating the quality of end-of-life
care, Bookbinder et al. (2015) generated a large pool of questions related to processes and
outcomes of quality of end-of-life care. The authors then collected the questions into three
separate instruments to use in a prospective survey of care provided to patients who died in the
hospital. A committee of members from hospital administration, medicine, nursing, social work,
ethics, chaplaincy, and education was established to write questions. Questions were based on
literature describing the best practices in palliative care, and the process was described as
iterative. Similarly, to assess mental health services, Wisdom et al. (2012) worked with clinicians
and administrators to create 31 measurable criteria and examples from standards of care to
design a licensing instrument. Ross et al. (2017) also created a multidisciplinary team from
different departments and specialties, including primary care, nursing, quality management, and
information technology to evaluate pain reassessment processes in a primary care clinic. The
process included a review of the electronic medical record (EMR), observation of clinic
workflow, and evaluation of clinic documentation and workflow.
Conducting a mock tracer. To conduct a mock tracer, TJC (2011) suggests teams
consider several options when assigning the role of surveyor. Teams can consider a surveyor
who is an expert in an area similar to the department, program, or service being assessed, but
caution teams not to assign surveyors to the same area they work, in order to ensure objectivity.
Alternatively, a team can choose to assign a surveyor with no experience in the area, but then
must be sure to provide enough time for the surveyor to prepare and become familiar with the
requirements. Pairing surveyors is another option as it allows surveyors to learn from each other.
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Prior to conducting the tracer, the department, program, or service within the organization should
be notified of the possibility of the mock tracer. When the tracer is commenced surveyors will
collect data by taking notes of observations, conversations, and review of documents. Surveyors
should be methodical and detail oriented, remind interviewees of the purpose of the tracer,
maintain focus, but also remain flexible and productive. It is also advised that the surveyor is
prepared to address any problems with the tracer that may be identified during the survey,
including logistical issues, staff cooperation, and time involved. Once each tracer is completed,
especially the first few tracers, it is recommended the team meets to debrief about the tracer
process by allowing each team member to share and discuss issues they encounter.
To assess end-of-life care, Bookbinder et al. (2015) conducted a survey that included a
review of the medical record and interviews with physicians, nurses, social workers, and
chaplains who provided care in the 48 hours prior to the patient’s death. The data was then
analyzed to determine which questions could be used in a smaller survey, but still capture the
more detailed information obtained when the three instruments were used. Next, a field test was
conducted to determine if a clinician-led tracer could effectively be used to assess end-of-life
care. Prior to the field-test, the nurse manager of a palliative care unit was trained by the survey
creators in tracer methodology, specifically regarding obtaining information from front-line
clinicians and the chart used to rate survey items.
In an assessment of mental health services, Wisdom et al. (2012) implemented a toolkit
which included documents associated with the licensing process, video presentations related to
standards of care and implementing best practices, a question and answer page to address topics
raised by providers and other stakeholders, and an email address for questions, suggestions,
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issues, and comments. Protocols were in place to select tracer cases, and field tests were
conducted by central office and field office staff.
To evaluate pain reassessment processes, Ross et al. (2017) reviewed the EMR of
patients who received Toradol, then utilized tracer methodology to track patients’ process
through clinic workflow and noted compliance for the same pain reassessment requirements as
was reviewed in the EMR. A workflow questionnaire was also administered to capture the pain
reassessment process and clinic procedures for clinic staff. With regards to patient selection,
authors Padgette and Wood (2018) state that selections of patients can be random or targeted
based on the tracer goal, but note it is important to ensure the number and type of patients
observed allow for adequate validation of the practices or processes being evaluated. However,
in the study conducted by Ross et al. (2017) the tracer sample size was purposely small in order
to allow comprehensive evaluation of pain reassessment practices during observations. Though
the authors acknowledge, the small sample size limits the generalizability of the findings.
Analyzing tracer data. Organizing and analyzing the data collected from the mock
tracer is important in order to review, rank, and prioritize the problems and issues uncovered.
TJC recommends several methods for organizing data, including developing a method to
categorize the completed forms, previewing the data to check for recording errors and to
highlight areas of concern, and ranking problems based on the data analysis. Once the data is
analyzed, the results should be reported, but not presented in a way that may be perceived as
punitive or that portrays the mock tracer as an inspection. All identifying information should be
removed. TJC suggests several ways to report results, including formal reports, conference calls
to share results, or posting feedback on an internal organization site or room and asking for
feedback. Also important is presenting information in a timely manner, specifically, within one
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month after completion and highlighting positive outcomes in order to encourage future positive
interactions with mock tracers.
The methods used to analyze data can remain the discretion of the organization.
Bookbinder et al. (2015) utilized factor analysis, canonical correlation, and group comparisons to
determine if correlations could be made between instrument items and latent variables.
Ultimately, the data was analyzed to determine if a clinician tracer guided by a small number of
items could effectively be used as an audit tool. The items used on the field test were chosen
based on the results of the preliminary analysis of the pilot and survey proper. Wisdom et al.
(2012) do not discuss the process used to analyze data, but the authors share the field tests helped
to identify strengths and weaknesses of the instrument as a licensing tool. Additionally, the field
tests helped to establish the feasibility of using tracer methodology, identify the strength of the
scoring protocol, and enable the staff to work together to ensure the survey was conducted
consistently. Likewise, Ross et al. (2017) do not discuss the use of statistical analysis to analyze
results, but workflow processes were identified, and workflow analyses revealed the roles
performed by staff nurses, which was then used to guide clinic policy.
Applying results. The final step of conducting a mock tracer is to develop and
implement improvement plans. Suggested approaches to implementing plans include handing off
corrective actions to relevant managers, working with the organization’s performance
improvement program, sharing plans with the entire organization, monitoring plans as they are
implemented by appropriate departments, and preparing for future mock tracers (TJC, 2011).
The tracer conducted by Ross et al. (2017) revealed the absence of standardized
procedures in the clinic for pain reassessment. Therefore, the project improvement team
recommended workflow be reviewed and modified and recommendations for improvement were
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provided. The authors also acknowledge the importance of including primary care staff, EMR
trainers, and clinical workflow analysts in the review and evaluation of possible solutions.
Bookbinder et al. (2018) created a tracer tool based on staff feedback and the results of the field
test. The authors concluded that findings revealed using the tracer tool would not be definitive,
but instead would suggest the need for more detailed evaluation, practice change, or staff
training. Similarly, Wisdom et al. (2012) concluded tracer methodology provided a more
accurate assessment and follow-up of clinical issues compared to the process that emphasized
policies and procedures, meeting minutes, and adherence to medical record documentation. Staff
also revealed the process was more collaborative, affirming, and clinically relevant and ended
with more agreement and clarity on clinic functioning. Overall, the implementation of
interventions utilizing tracer methodology result in positive and valuable outcomes, however, the
application of tracer methodology is not without challenges.
Summary of evidence. Several studies note the importance of cooperation from staff and
leadership. Wisdom et al. (2012) found mental health service providers were reluctant to share
information about service users and other providers. Ross et al. attribute success to having
leadership support and recognize conducting a stakeholder analysis helped to identify and engage
appropriate staff members. Bookbinder et al. (2018) also acknowledge the cooperation and
capabilities of the professionals in their study may not be applicable to other settings.
Furthermore, the authors recognize that some tests conducted by staff in their own unit may be
subject to bias, indicating the need for future studies to assess for rater bias. With regards to the
sustainability of implementing tracer methodology for program evaluation, Wisdom et al. (2012)
note the challenges in continuously incorporating feedback from clients and providers and
ensuring consistency among the survey team. Likewise, Bookbinder et al. (2015) recognize that
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the tracer tool utilized in their study requires validation in new samples, and the tracer should be
tested and retested to evaluate the reliability and sensitivity to change. The authors comment that
the results of the tracer are not definitive, but indicate a need for further assessment, change, or
education.
Overall, the reviewed studies suggest tracer methodology can be used not only to audit an
organization’s policies and procedures, but as a means to evaluate system programs and staff
performance. Information gathered from a tracer can aid organizations in creating new programs
or improving existing programs by helping to identify deviations or deficits. Furthermore, by
measuring more than process outcome measures, tracers also have to potential to provide reasons
for certain patterns or deviations. Ensuring multidisciplinary input when creating a tracer appears
paramount, as does ensuring surveyors are not prone to biases when conducting the survey.
Additionally, allowing adequate time for surveyors to become comfortable in their role is
important as the success of the survey relies strongly on the abilities of the surveyor. None of the
studies reviewed discussed evaluating the consistency of tracers conducted by multiple
surveyors, however, given the reliance of tracers on surveyors, if more than one surveyor is
assigned, consideration should be given to inter-rater reliability.
Conceptual Framework
The integrated promoting action on research implementation in health services (iPARIHS) is the framework that guided the implementation of the tracer in the acute care setting
(Kitson & Harvey, 2016). Kitson and Harvey (2016) examine knowledge translation (KT), also
known as evidence-based practice. KT is the process of developing knowledge into practical
applications for clinical practice and patient care. The authors note that historical models of KT
are based on linear models of translation with the assumption that knowledge producers and
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knowledge users are two separate entities. However, Kitson and Harvey (2016) cite evidence that
multifaceted or complex interventions are more effective than simple interventions and suggest
the use of the i-PARIHS framework to introduce KT principles into practice. Furthermore, the
authors cite evidence that facilitation is a key component of KT, and is effective in primary care,
community development, and acute and sub-acute care settings.
According to the original PARIHS framework, successful implementation of evidencebased practices relies on the quality and type of evidence, the characteristics of the setting or
context, and the methods used to introduce or facilitate the uptake of the evidence. The core
constructs of the i-PARIHS framework are facilitation, innovation, recipients, and context.
Facilitation, the process of supporting individuals, groups, or teams to collectively work to
achieve a common goal, is highlighted as being the active component in assessing, aligning, and
integrating the other constructs (Kitson & Harvey, 2016; Schwarz, 2002). In order to effectively
utilize a tracer as a means to evaluate a hospital ASP, facilitators were important to encourage
the integration of tracer methodology (innovation) into the assessment practices of the hospital
and ASP team in the acute care hospital (recipients and context) . A Doctor of Nursing Practice
(DNP) student was designated as the novice facilitator, an administrative nursing director and a
regional clinical coordinator pharmacist served as the experienced facilitators, and the medical
director of pharmacy and infection control served as the expert facilitator.
Specific Aims
The goal of the project was to utilize tracer methodology to assess the effectiveness of a
San Francisco Bay Area community hospital’s antimicrobial stewardship interventions through
the evaluation of healthcare providers’ awareness of antimicrobial stewardship within their
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institution, knowledge regarding antimicrobial stewardship components, and approach to
prescribing antibiotics and ordering diagnostics for patients with CAP by August 2020.
Methods
Context
Implementing an antimicrobial stewardship tracer in a hospital setting required
participation and cooperation from several key stakeholders. The Medical Director of Pharmacy
and Infection Control was aware of the need to explore tracer methodology to evaluate the ASP,
and buy-in from the ASP team members and hospital leaders, including the antimicrobial
stewardship pharmacist lead, the hospitalist lead, the pharmacy director, a nursing administrative
director, and nurse managers, were necessary in order to convey the importance of the tracer to
other staff members and leaders within the hospital. Additional key stakeholders included the
internal medicine physicians, clinical pharmacists, and nurses, all of whom were interviewed
during the tracer process.
Care of patients in the hospital is multifaceted and involves input from numerous
individuals, disciplines, and specialties. Capturing information from one component of patient
care is challenging as the care team and treatment team is constantly changing and evolving.
Understanding the process in which patients are assessed and admitted to the hospital was
important in order to create a tracer that would best capture stewardship practices and potentially
elicit obstacles or outside influences of different actions, attitudes, or behaviors.
Intervention
The purpose of the intervention was to implement tracer methodology to assess the
hospital ASP. Tracer methodology follows patients through the health care delivery system
collecting information related to treatment or services to evaluate care provided. Tracer surveys
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enable assessors to identify potential issues regarding performance issues within processes, or
with interfaces between processes (TJC, 2018).
Gap analysis. The current and past ASP evaluation methods of the hospital included
audit and feedback, rates of usage of specific antibiotics, and prescribing rates of individual
prescribers. In planning, developing, and conducting a tracer, then analyzing and sharing the
data, the objective of the intervention was to create a tool to determine current antimicrobial
prescribing practices when treating CAP, identify barriers to stewardship, and evaluate the
knowledge of healthcare providers regarding antimicrobial stewardship (see Gap Analysis,
Appendix C).
The tracer in and of itself helped to identify gaps within the hospital ASP. At the
individual patient level, the tracer assessed patient care regarding diagnostic criteria, ordered
tests, and prescribed antibiotics. At the system level the tracer assessed if the hospital ASP has
been effective in distributing education regarding antimicrobial stewardship and is a
distinguishing resource for clinicians. The results of the interview portion of the tracer were
compared to the information collected from the patient chart to determine if an association exists
between antimicrobial prescribing practices and confidence regarding antimicrobial stewardship.
Gaps in patient care were identified based on information collected during the tracer.
Work breakdown structure and Gantt chart. Implementation of the tracer involved
four components: planning, conducting, analyzing, and sharing (see Work Breakdown Structure,
Appendix D). The process of creating and implementing the tracer for antibiotic stewardship
began with creating a multidisciplinary team with representatives from infectious disease,
pharmacy, and nursing. In the planning phase, the team met multiple times to determine the
scope of the tracer and establish a schedule for creating and conducting the tracer. (see Gantt
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Chart, Appendix E). It was important to designate who would be performing the survey in order
to begin preparing the surveyor by establishing access to the EMR, providing education about
ASP guidelines and standards, and offering methods for conducting the tracer.
The DNP student assumed the role of surveyor, and while the tracer was being
developed, the process of introducing the surveyor to clinical staff began. An introductory letter
was sent from the experienced and expert facilitators to clinical staff to introduce the surveyor
and the project. Additionally, the surveyor attended patient rounds for several weeks leading up
to the tracer to meet as many hospitalists, clinical pharmacists, and nurses in person as possible,
and, as time permitted, was introduced to nursing managers and clinical pharmacy directors and
staff by the experienced and expert facilitators. The surveyor was also granted access to the
electronic medical record and provided with contact information for prescribers and clinical
pharmacists, all of which was facilitated by one of the experienced facilitators.
To choose components that would be best reflect the overall impact of the ASP through
meeting compliance standards, it was necessary for all team members to review the CDC’s Core
Elements of Hospital Antibiotic Stewardship Programs: 2019 (CDC, 2019c), TJC’s New
Antimicrobial Stewardship Standards (TJC, 2016), and the American Thoracic Society’s (ATS)
guidelines for diagnosing and treating adults with CAP (Metlay et al., 2019). The
multidisciplinary team met multiple times to determine the overall goals of conducting the tracer,
including which questions and metrics would provide the most useful feedback for the
stewardship program. It was important to ensure that tracer questions reflected components of
the Core Elements. After deciding the tracer would focus on patients being treated for CAP, the
team worked to integrate components of the ATS guidelines into the tracer. Additionally, the
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team created interview questions for healthcare practitioners, with the goal of obtaining current
practices and self-perceived knowledge.
Once the tracer was created by the Medical Director of Pharmacy and Infection Control,
the Clinical Coordinator Pharmacist, and the DNP student who comprised the multidisciplinary
team tasked with creating the tracer (see Appendix F), the surveyor (also the DNP student)
conducted several chart reviews with the tracer to identify any preliminary issues with questions
or the tracer format. The surveyor then presented the findings to the rest of the multidisciplinary
team and modifications were made as necessary. Once the tracer was finalized, the surveyor
began conducting the tracer with staff interviews.
Patient charts were selected to be surveyed if the patient had an admitting diagnosis of
CAP; pneumonia due to infectious organism; or multifocal pneumonia. When a chart was
identified, it was reviewed by the surveyor and used to answer questions in the ‘Infection
Specific Questions’ and ‘All Pneumonia’ sections of the tracer which identified various
components of care, including diagnostic criteria, laboratory and radiology testing, and ordered
antibiotics. The admitting physician was notified and attempts were made to contact him/her for
the interview portion of the tracer which included questions related to their knowledge of
antimicrobial stewardship and the hospital ASP, and specifically the clinical approach to the
patient. If more than five days had passed from the time the patient was admitted, the physician
was not contacted. Additionally, an attempt was made to interview a nurse taking care of the
patient on the day the tracer was conducted, as well as the clinical pharmacist responsible for
reviewing the patient’s medications for the day, to ask questions related to their general
knowledge of antimicrobial stewardship, the hospital ASP, and the care of the selected patient.
Patient charts were excluded if pneumonia was suspected but antibiotics were not ordered; the
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patient was diagnosed with COVID-19; the patient met the criteria for healthcare associated
pneumonia; the patient was originally admitted to the intensive care unit; the patient was
ventilated or had a tracheostomy.
The first tracers conducted in February 2020 were conducted in-person whenever
possible. The surveyor conducted tracers twice a week until the onset of the COVID-19
pandemic, at which point, tracers were halted. Tracers resumed in May 2020 but were conducted
remotely, with the interview portion of the tracer conducted via telephone. The tracers were
conducted twice a week, however, conducting the interview portion by phone allowed more
flexibility as to the days the surveyor could attempt to contact providers. As the tracers
progressed, the surveyor met with at least one member of the multidisciplinary team every two to
four weeks to review challenges encountered with implementing the tracer and discuss any
issues or observations made regarding the tracer tool or methodology.
It was important for the surveyor to remain flexible while conducting the survey to meet
the needs of the patient care team. The ability to conduct face to face interviews was helpful in
establishing a connection with the staff member being interviewed, however, it had the potential
to limit the available timeframes the surveyor could reach staff. In fact, even when in-person
interviews were conducted, there were still times the surveyor conducted an interview via phone
due to the availability and preference of staff. After the onset of the COVID-19 pandemic, all
tracers were conducted remotely. The ability to conduct tracers remotely potentially provided the
surveyor with more flexibility with regards to days and time spent dedicated to conducting the
tracer and interviews. Unfortunately, conducting the tracer remotely may have contributed to
staff being unfamiliar with the mock tracer and, therefore, more apprehensive to share
information.
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Once tracers were completed, the last step of the implementation was consolidating the
data and organizing it in a meaningful way for provision to the multidisciplinary team. Results
and lessons learned throughout the process were also presented to the systems regional
Antimicrobial Stewardship Team. Additionally, a toolkit (Appendix G) was created to guide
hospitals in the plan, design, and implementation of future ASP tracers.
Responsibility/communication plan. The i-PARIHS framework guided the
implementation of the tracer, and as such, guided communication and assignment of tasks
amongst facilitators and from facilitators to recipients. According to the constructs of the iPARIHS framework, the novice facilitator was selected to lead the project with support from the
experienced and expert facilitators (Kitson & Harvey, 2016) (See Responsibility/Communication
Plan, Appendix H). The novice facilitator worked to apply evidence in healthcare to innovations
in practice. In order to successfully link evidence to innovation, the novice facilitator learned
how to assess the quality of evidence and engage colleagues in discussion about current practices
and areas for improvement (Kitson & Harvey, 2016). The DNP student served as the novice
facilitator and conducted a review of tracer methodology, including past applications, and
reviewed antimicrobial stewardship guidelines to establish an understanding of ASP
requirements from TJC and CMS and present the findings to the established multidisciplinary
tracer team.
The DNP student worked to understand the organizational structure of the hospital, with a
specific focus on learning organizational priorities in order to garner support from hospital
leadership and senior management. As the novice facilitator, the DNP student was supported by
an administrative nursing director and regional clinical coordinator pharmacist serving as
experienced facilitators. The nursing administrative director helped to orient the novice

TRACER METHODOLOGY

27

facilitator to the hospital by familiarizing the novice to the setting, introducing the novice to
appropriate leaders and managers, facilitating access to the electronic medical record, and
facilitating remote access as necessary. Additionally, as an internal member of the organization,
the nursing director was able to positively promote the innovation to stakeholders.
The regional clinical coordinator pharmacist provided guidance by helping the DNP
student understand different ASP interventions and processes related to antimicrobial prescribing
in the hospital. Understanding how to implement new evidence into routine practices enabled
the experienced facilitators to support the novice facilitator with issues related to recipients and
context. The medical director of pharmacy and infection control fulfilled the role of the expert
facilitator by supervising the project and providing guidance to the DNP student. An expert
facilitator is able to work across academic, service, and other organizational boundaries to
actively incorporate evidence-based practices (Kitson and Harvey, 2016). In the implementation
of the tracer, the expert facilitator aided in troubleshooting various strategies and provided
insight into the potential strengths and weaknesses of implementing such methodology.
SWOT analysis. In conducting a SWOT analysis (see Appendix I for SWOT chart),
potential strengths of utilizing tracer methodology for ASP evaluation included: (a) the ability to
assess the knowledge of individual prescribers, pharmacists, and nurses regarding antibiotic
prescribing, (b) the ability to establish resources available to clinicians, and (c) the potential to
elicit the rationale regarding prescribing habits. Furthermore, tracer methodology enabled the
assessor to gather information directly from the EMR to evaluate the impact of system wide
interventions of education, antibiotic formularies, patient rounding, and diagnostic testing. While
interviews and chart reviews can be conducted on site, the nature of the tracer allowed for
information to be collected by phone or remotely, which helped to ensure efficiency for both
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staff and the assessor. The development of the tracer by a multidisciplinary team provided the
unique perspective of each profession. Additionally, the tracer focused on care provided for one
specific infection, allowing for a more focused assessment, and the chosen infection of
pneumonia has established treatment guidelines. Lastly, completion of the tracer by an outside
assessor provided the potential of less risk of bias.
Potential weaknesses included the time involved to conduct the tracer, as well as
coordinating prescriber and pharmacist schedules with the day the tracer was conducted. For the
purposes of this tracer, the practices of the admitting physician were evaluated, however,
questions pertaining to specimen collection and antibiotic timing and review required the patient
to receive care for more than the initial first day. The admitting hospitalist may not have been
available on day three of the patient’s hospital stay. Additionally, the clinical pharmacist
responsible for reviewing antibiotics on day three may not have been available every day. The
perception of prescribers, pharmacists, and nurses, and their willingness to cooperate and
participate also influenced the success of the tracer. The assessor had additional challenge of
earning buy-in from stakeholders who were unfamiliar with them. Also, the accuracy of the
tracer is dependent on the surveyor’s knowledge of the charting system and ability to find
information. Moreover, the tracer does not account for legitimate deviations from standard
antibiotic therapy.
Potential opportunities include the fact that tracer methodology is evidence-based and
utilized by accrediting agencies to evaluate various aspects of patient care and system processes.
In the instance of ASPs, a state government agency responsible for promoting hospital ASPs has
proposed the utilization of tracer methodology to evaluate the effectiveness of hospital ASPs as
TJC and the DNV-GL now use the Core Elements as a basis for accreditation standards.
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Additionally, the questions posed to staff have the potential to become an indirect way of
providing antibiotic stewardship education and impress the importance of ASPs within the
hospital.
Potential threats to implementing tracer methodology for the evaluation of ASPs within
hospitals include the financial investment to implement and sustain the program and the amount
of time involved to conduct the tracer. While the review of the electronic health record and
interview can be streamlined, infections such as pneumonia are multifaceted, therefore, the
approach to treating pneumonia can vary based on the patient. Such variation has the potential to
confound data if questions lack direction or the surveyor is inexperienced or unfamiliar with the
process. The tracer as a source of information is only as valuable as the surveyor is conscientious
in data collection.
Budget and break-even analysis. The proposed budget considered the number of hours
required by the employees with the largest contributions of time when developing and
implementing the tracer. Hours for the medical director of pharmacy and infection control and
the regional clinical coordinator pharmacist were related to the creation of the tracer and
provision of guidance and feedback as needed. The DNP hours were accrued based on time spent
creating and implementing the tracer.
The incremental cost to treat an antibiotic resistant infection is: $1,383 per patient
(Thorpe, Joski, & Johnston 2018). Therefore, if the total cost to develop and implement the
tracer is $16067, to break even, antimicrobial resistant infections need to be prevented in 12
people (see Appendix J for Budget and Break-Even Analysis).
Study of the interventions. Data was collected using the proposed tracer (see Appendix
F). The face validity of the tracer was determined during the creation of the tracer. The first draft
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of the tracer was distributed to all members of the survey team to review. The tracer was revised
according to comments and suggestions received, then distributed to members again for final
approval. Content validity was assessed once the survey was complete and data was analyzed
and discussed. During the course of the survey, the surveyor determined that certain questions
were not effective as the intervention was difficult to assess from a review of the chart, or the
question implied the intervention was being implemented and practiced, when, in fact, it was not.
Additionally, the surveyor noted questions found to be non-specific, therefore making the
answers more susceptible to being misinterpreted.
Measures
The main goals of the tracer (see Appendix F) were to evaluate antimicrobial stewardship
awareness and knowledge of physicians, clinical pharmacists, and nurses working at the hospital.
The outcome measures were related to questions assessing clinician knowledge and awareness
during the interview portion, and treatment approaches collected during the EMR tracer.
Outcome measures included: Physician knowledge of hospital ASP; nurse knowledge of hospital
ASP; clinical pharmacist knowledge of hospital ASP; physician self-reported confidence
regarding pneumonia treatment; and compliance with ATS treatment guidelines for CAP.
Specifically, the tracer was expected to capture the percentage of interviewed providers
aware of the ASP and using appropriate antimicrobial prescribing protocols. Data collected
through interviews was compared to data collected from the EMR, with the intent of identifying
strengths or weaknesses in antimicrobial stewardship practices as they related to the self-reported
knowledge and confidence surrounding stewardship by the healthcare providers. Qualitatively,
observations made by the surveyor regarding the attitudes of providers toward being interviewed
and toward specific questions were also noted.
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Analysis
The surveyor deidentified information from the charts and interviews and filed the forms
electronically as the tracers were being completed. Once all the tracers were completed, the
surveyor reviewed the data to ensure all information was recorded and coded correctly. The
yes/no questions and answers were tabulated using an Excel spreadsheet. The answers to the
questions which allowed open answers were coded according to identified categories and
themes.
To analyze the collected information, answers were organized into tables and charts from
Excel, and then data from the interview portion of the tracer was compared to the data collected
from the patient chart. The intention of comparing data from the two parts of the tracer was to
determine if an association existed between antimicrobial prescribing practices, confidence
regarding antimicrobial stewardship, and self-reported knowledge regarding antimicrobial
stewardship.
The small number of patient charts reviewed, and smaller number of clinicians
interviewed, created a limitation when interpreting the results. However, as there are a set
number of staff within the hospital, and repeat interviews within the same tracer cycle are not
desirable, an increased number of chart reviews would perhaps only aid in a better understanding
of the processes taking place. Data collected on the proposed outcome measures could still be
analyzed, but attention was shifted to also include knowledge garnered through observations
regarding methodologies applied during the tracer. Such observations can help to guide future
tracers and provide insight into the stewardship knowledge and practices of healthcare providers
within the hospital.
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Ethical Considerations
This project was evaluated and approved as a quality improvement project through the
University of San Francisco School of Nursing and Health Professionals (see Appendix K for
Statement of Non-Research Determination). The project was undertaken as an evidence-based
change of practice project and as such, did not need to be supervised by the Institutional Review
Board. Priority was given to confidentiality and privacy by blinding data retrieved from the
EMR. Ensuring patient privacy during chart audits was essential, as was maintaining
confidentiality of prescribers, clinical pharmacists, and nurses during interviews. To protect the
identity of patients and healthcare personnel, a coding system was implemented to de-identify
the hospital, interviewee, and patient.
Collecting information and data regarding antimicrobial prescribing practices and barriers
to antimicrobial stewardship was done with the ultimate goal of improving patient care and
preserving antimicrobials for future use. The purpose of this project was in accordance with the
Jesuit values and the American Nurses Association (ANA) Code of Ethics. The implementation
and outcomes served to fulfill a social responsibility of creating, communicating, and applying
knowledge that will assist with responsible utilization of healthcare resources (University of San
Francisco, n.d.). Furthermore, according to Provision 6 of the ANA Code of Ethics, in order to
encourage safe, quality healthcare, the nurse is expected to establish, maintain, and improve the
ethical environment of the work setting (American Nurses Association, 2015). Implementing
tracer methodology to evaluate a hospital ASP seeks to create a new assessment method to
improve and encourage antimicrobial stewardship which supports nurses and other health
professionals in the fulfillment of their ethical obligations.
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Results
In total 15 tracers were completed from February 2020 to July 2020, with a pause in
conducting tracers from the beginning of March to the end of May due to COVID-19. Within the
15 tracers, seven physician interviews, nine nurse interviews, and five clinical pharmacist
interviews were conducted. The focus of the tracer was on the admitting physician, nurse caring
for the patient on the day of the tracer, and the clinical pharmacist caring for the patient on the
day of the tracer. The data being collected, however, was often generated over several days and
in the days preceding the tracer.
Tracer Results
All raw data was provided to the hospital medical director of pharmacy and infection
control and the regional clinical coordinator pharmacist, however, as the onus of antimicrobial
stewardship in the hospital falls to physicians, results from the physician interviews and EMR
review were highlighted in the presentation to the regional System Antimicrobial Stewardship
committee (see Appendix L and Appendix M). Specifically, with regard to general knowledge of
the hospital ASP, it was noted that of the seven physicians interviewed, six stated they were
aware of the hospital ASP prior to being interviewed, five recognized the hospital had specific
guidelines for common infections, and all seven stated the hospital implemented specific
antimicrobial stewardship interventions. However, when asked to specify interventions, answers
varied widely. Answers included the following responses: (a) someone calling to review
prescribing, (b) receiving a prescribing report with the overall percentage of antibiotics
prescribed for select antibiotics, (c) patient rounding, (d) antibiotic specific education, (e) order
sets, and (f) receiving input from the pharmacy. Only education, patient rounding, and
prescribing reports were cited by more than one physician. With regards to self-reported
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knowledge, all physicians interviewed stated they had adequate knowledge of the treatment of
pneumonia to choose empiric antibiotic therapy. Of the EMRs reviewed, all patients were
appropriately prescribed standard empiric therapy.
Factors influencing treatment revealed some inconsistencies with chart documentation
and following guidelines. Physicians reported the following multiple resources used to determine
a definitive antimicrobial regimen: (a) clinical guidelines, (b) clinical condition of patient, (c)
procalcitonin level, (d) minimum therapy of three days for treatment, (e) culture and sensitivity
results, (f) infectious disease consult, (g) UptoDate, (h) type of infection, and (i) clinical
improvement of the patient. Only clinical guidelines, clinical condition, and infectious disease
consult were cited by more that one physician.
The EMR review sought to detect diagnostic criteria identified by the ATS/IDSA clinical
practice guidelines for the treatment of CAP. Of the 15 patient charts reviewed five patients were
tested for influenza, nine patients were not tested, and one patient chart was missed. The
guidelines state patients should be tested when influenza was circulating in the community
(Metlay et al., 2019). It was noted that this result is somewhat difficult to interpret as the tracer
was halted from March to June, but it may have been easier to interpret if results were collected
from charts in winter and early spring when influenza is more prominent. Other diagnostics
reviewed included urine tests for Legionella and pneumococcal antigens. The recommendation is
to not routinely check for these antigens except in patients with severe CAP (Metlay et al.,
2019). Only three of the patient charts reviewed met IDSA/ATS criteria for severe CAP, yet
seven patients were tested for the Legionella antigen and four were tested for the pneumococcal
antigen. The discrepancy in Legionella and pneumococcal antigen testing is interesting, as is the
divergence in the number of patients tested for Legionella and pneumococcal antigens compared
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to the number of patients meeting the diagnostic criteria for severe pneumonia. Lastly,
procalcitonin is not recommended to determine need for initial antibiotic therapy, but it is
acknowledged it may be helpful to monitor (Metlay et al., 2019). Of the patient charts reviewed,
nine patients had a serum procalcitonin level ordered prior to the initiation of antibiotics or prior
to the second dose of antibiotics, but six did not.
Of the questions related to factors influencing treatment of MRSA, P. aeruginosa, and
other MDROs, physicians cited multiple criteria to determine risk for such organisms. The intent
of the questions regarding MDROs was to evaluate knowledge regarding risk factors and
treatment. The answers were found to be varied and inconsistent. Criteria cited included: (a)
prior isolation of P. aeruginosa, (b) prior isolation of MRSA, (c) recent hospitalization and
exposure to parenteral antibiotics, (d) arrival from facility with known MDROs, and (e) an
‘other’ category. The EMR review revealed vancomycin was ordered for three of the 15 patients,
however, a MRSA PCR was only ordered for one of the three patients. A pretreatment gram stain
and culture of lower respiratory secretions was ordered for three patients, but the three patients
for which the gram stain were ordered differed from the patients for whom vancomycin was
ordered and the patients did not meet the criteria for severe-CAP according to the
documentation. The guidelines recommend obtaining a pretreatment gram stain and culture of
respiratory secretions in adults being treated for CAP in the hospital who are classified as severe
CAP, or are being empirically treated for MRSA or P. aeruginosa, or who were previously
infected with MRSA or P. aeruginosa, or who were hospitalized and received parenteral
antibiotics in the last 90 days (Metlay et al., 2019).
Data presentations. The final step of the tracer was presenting the results of the tracer
and lessons learned about applying the methodology to ASP assessment to the hospital medical
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director of pharmacy and infection control and the regional clinical coordinator pharmacist (see
Appendix L). Additionally, some results and the lessons learned regarding methodology were
presented to the regional System Antimicrobial Stewardship committee of which the medical
director of pharmacy and infection control and the regional clinical coordinator pharmacist are
members. Results were communicated in a written report which presented data collected for each
question on the tracer. Qualitative data was provided from interview questions, and annotations
were added to questions found to need clarification or revision. A PowerPoint presentation was
also created for the regional System Antimicrobial Stewardship committee and presented
virtually during a regularly scheduled meeting (see Appendix M).
Tracer observations/recommendations. Collecting data retrospectively provided
insight into the approach to caring for patients with a diagnosis of CAP and highlighted that
caring for such patients is a team approach. The surveyor observed that often when the admitting
physician admits the patient, the initial orders do not necessarily include all recommended
diagnostic tests, but the tests may eventually be ordered by consulted specialists or hospitalists
on subsequent days. Thus, with regards to lessons learned in applying tracer methodology for
ASP evaluation, it was concluded future tracers must carefully consider the presentation of
questions and designate medications, tests, and processes by specialty or department to help
establish progression of treatment and propensity of providers.
With regards to staff participation, including attitudes toward the tracer, it was noted that
willingness to participate and enthusiasm varied by discipline. Regardless of discipline,
willingness to participate was greatly influenced by current workload. Amongst physicians,
attitudes toward participation also seemed to be influenced by past experiences with feedback
related to their antimicrobial prescribing practices.

TRACER METHODOLOGY

37

Incidentally, the surveyor also found some uncertainty existed regarding the classification
of the severity of patients’ pneumonia complicating some aspects of the tracer. Aside from
reviewing the chart for criteria from a validated definition, there is no standardized designation
in the patient chart to distinguish CAP from Severe-CAP. The clinical practice guidelines
approved by the American Thoracic Society (ATS) and Infectious Disease Society of American
(IDSA) in 2019 provide criteria for defining severe-CAP and use the distinction to indicate
which diagnostics are recommended. Future tracers should further evaluate the sensitivity and
specificity of the criteria as it pertains to patients admitted to the hospital for CAP. No physicians
cited the ATS and IDSA guidelines and several physicians listed criteria not included when
determining the course of treatment for patients.
The results of the tracer can be used as an educational opportunity for participants,
though, ultimately, the ASP team is responsible for reviewing the results and planning future
interventions. Additionally, as knowledge and insight evolved regarding the creation and
implementation of an ASP tracer, a toolkit was developed to guide future efforts. The
implementation toolkit (see Appendix G) includes guidance regarding selection of team
members, recommendations for strategies to create the tracer tool, and offers considerations to be
made when deciding metrics to be investigated.
Discussion
Summary
Antimicrobial stewardship will remain an important part of providing safe, quality
healthcare, therefore, healthcare facilities must find ways to efficiently and effectively evaluate
programs. Utilizing a method that evaluates process measures while simultaneously assessing
barriers to appropriate antibiotic prescribing has the potential to provide valuable feedback and
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empower involved stakeholders to meaningfully contribute to quality improvement projects
within their institutions. The completed tracers provided insight into the effectiveness of the ASP
program and helped to identify trends with regards to resources used, efficacy of currently
utilized feedback methods, and potential knowledge gaps. The ability of a tracer to provide
valuable information relies heavily on the quality of questions and the ability of the surveyor to
understand and identify questions that may provide imprecise answers. Often, survey questions
aspire to have definitive answers, however, answers may not always be interpreted definitively in
the context of the multifaceted nature of patient care in an inpatient setting, under the
circumstances of an evolving infection, and during transfer of care between providers and
departments.
Future application of tracer methodology to evaluate antimicrobial stewardship must be
sensitive to the multiple providers and departments involved in caring for patients receiving
antimicrobials. Future tracers should remain sensitive to the time required of staff to participate
in the tracer, including considering the use of e-surveys to obtain information for follow-up
(North et al., 2009). Some information may best be collected in the form of a survey or
interview, but the value of requesting staff to demonstrate the location of items in the chart, for
example, an order set, versus questioning knowledge of an item should not be underestimated.
Such a technique allows more accurate assessment and potentially decreases the provider’s
perception that their judgement or knowledge is being tested.
If a tracer can successfully be created and implemented to evaluate a hospital ASP, then
applying the method to evaluate ASPs in outpatient and long-term care facilities should also be
considered, as antimicrobial stewardship recommendations exist for these institutions which are
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also subject to review from TJC and CMS (CDC, 2015; CMS, 2016; Sanchez et al., 2016; TJC,
2019).
Interpretation
As was demonstrated in other projects in which a tracer was developed and implemented,
the establishment of a multidisciplinary team was an important component in the development of
the ASP tracer (Bookbinder et al., 2015; Padgette & Wood, 2018; Ross et al., 2017; Wood et al.,
2012). Just as Wisdom et al. (2012) noted providers were reluctant to share information about
service users and other providers, the ASP tracer found that providers were not only sometimes
reluctant to answer questions, but also suspicious as to why the information was being collected.
While leadership provided support for the project and facilitated its implementation, increasing
the visibility of the project in future tracers and involving more stakeholders may lessen such
reluctance. Moreover, the importance of choosing appropriate methods to introduce the project
and the role of facilitation in implementing a new practice in the hospital was evident in the
reluctance displayed by many staff members. Understandably, many resources were directed
toward the COVID-19 pandemic, but future tracers must be prioritized by experienced and
expert facilitators to integrate tracer methodology as an assessment method within the hospital
(Kitson & Harvey, 2016).
Assigning a surveyor from outside the hospital potentially limited bias but may also have
contributed to reluctance to participate. In fact, future endeavors may wish to involve hospital
clinical pharmacists more, as stewardship pharmacists are likely key in ensuring trust amongst
other providers with respect to the tracer. With regards to specifically implementing the tracer,
Bookbinder et al. (2015) highlighted the importance of training the surveyor in tracer
methodology and obtaining information from front-line clinicians. Indeed, the ability of the
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surveyor to effectively obtain information from staff during the ASP tracer hinged on knowledge
of tracer methodology, familiarity with the tracer questions, and the ability to make observations,
while collecting data. If data is collected by hospital staff, assessing for rater bias will be
necessary (Bookbinder et al., 2018). Furthermore, if a tracer is conducted by more than one
surveyor, testing inter-rater reliability will also be important.
Padgette and Wood (2018) noted it is important to ensure the number and type of patients
observed allow for adequate validation of the practices and processes being evaluated. While the
sample size in the ASP tracer was small, focusing on patients with CAP provided a more focused
outcome, which was helpful when reviewing a process as multifaceted as antimicrobial
prescribing and stewardship. Unfortunately, the small sample size also makes the results less
generalizable.
Ross et al. (2017) identified workflow processes and roles of staff with a tracer and
applied the knowledge to guide clinic policy, the observations and lessons learned in the ASP
tracer with regards to staff receptiveness, intention of questions, and focus of questions can be
applied to future assessments and education topics. Just as Wisdom et al. (2012) concluded that
tracer methodology provided a more accurate assessment and follow-up of clinical issues as
opposed to processes emphasizing policies and procedures, likewise, the ASP tracer revealed the
steps involved in prescribing antibiotics are not straightforward and are influenced by variables
not only related to the patient, but also to the provider, the specialty, the department, or even the
day.
Nevertheless, the various components involved in antimicrobial stewardship that make
utilizing tracer methodology an appealing assessment technique also contribute to the challenges
of implementing future tracers in a sustainable manner. Wisdom et al. (2012) note the challenges
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in continuously incorporating feedback and ensuring consistency among the survey team, and
Bookbinder et al. (2015) observe that tracers continuously require testing and validity to evaluate
reliability and sensitivity to change. Maintaining a tracer that is current and relevant to the
practices within the hospital, and ensuring surveyors are consistently and uniformly educated
requires a commitment and investment from hospital administrators. Yet, an ASP tracer has the
potential to fulfill the required core elements of tracking, reporting, and education as the tracer is
capable of collecting data related to antimicrobial prescribing practices and indirectly educating
staff on antimicrobial stewardship. Moreover, results can not only be shared with staff, but can
also be used to guide further evaluation, influence policies, and inform educational interventions
(Bookbinder et al., 2018; Wisdom et al., 2012).
Limitations
The project was to be initiated early 2020 with the first tracers to be conducted in
February which seemed advantageous when attempting to survey as many cases of CAP as
possible based on the usual seasonal trend of increased CAP admissions in the winter and spring
seasons (Murdoch, et al., 2014). However, arguably the biggest limitation in conducting this
particular tracer was the occurrence of COVID-19. Surveys had to be halted at the beginning of
March, then resumed at the end of May and continued until the middle of July, though the
number of cases able to be captured on days the surveyor was able to conduct tracers decreased
over time. The small number of patient charts reviewed, and smaller number of clinicians
interviewed created a limitation when interpreting the results.
The first tracers conducted in February were conducted in-person whenever possible. The
ability to conduct face to face interviews was helpful in establishing a connection with the staff
member being interviewed, however, it had the potential to limit the available timeframes the
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surveyor could reach staff. In fact, even when in-person interviews were conducted, there were
still times the surveyor conducted an interview via phone due to the availability and preference
of staff. After the onset of the COVID-19 pandemic, all tracers were conducted remotely. The
ability to conduct tracers remotely potentially provides the surveyor with more flexibility with
regards to days and time spent dedicated to conducting the tracer and interviews. Unfortunately,
conducting the tracer remotely may have contributed to staff being unfamiliar with the tracer
and, therefore, more apprehensive to share information. Furthermore, as the tracer focus is on
the diagnosis of CAP, the outbreak of COVID-19 presents a unique challenge as it has the
potential to cause viral pneumonia. Consideration must be given to the potential for the
pandemic to alter the approach of healthcare providers when caring for patients with pneumonia.
Remote access and phone interviews helped to minimize unnecessary exposure to non-essential
individuals.
Challenges were also encountered with regards to the willingness and ability of staff
members to participate in the interview. Physicians often cited being too busy as a reason to not
be able to answer questions. One physician did not have access to the electronic medical record
at the time of the interview and could not remember the patient in question. In several instances
the physician did not return messages requesting a return call in order to conduct the interview.
With regards to nursing staff, a major challenge was trying to find times the nurses were able to
answer questions. Often, nurses were called multiple times in an attempt to accommodate their
schedules. Additionally, when tracers were resumed in May, several nurses refused to answer
patient specific questions citing patient privacy. Staff seemed unfamiliar with the project despite
an introductory letter being sent to units at the beginning of the project. The clinical pharmacists
were often the easiest staff to contact for interviews. In only one instance did the clinical
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pharmacist state she did not have time, though she did return the surveyor’s call, but the surveyor
was unable to conduct the interview at the time.
In addition to challenges related to finding acceptable times to speak with staff, the
receptiveness and openness of staff varied amongst disciplines. The success of the interview
portion of the tracer hinged on the willingness of staff to answer candidly and honestly. Staff
members were continually reassured their responses were anonymous, however, it was not
uncommon for physicians to appear apprehensive, as evidence by questions such as, “Why did
you choose me?” or “What did I do wrong?” The attitude amongst nursing staff varied with some
nurses appearing eager or enthusiastic, as evidenced by the details shared in their answers, while
others appeared rushed as evidenced by the need to end interviews early and answers that were
vague. The clinical pharmacists appeared the most open and eager to participate and share their
knowledge, observations, and thoughts.
Unfamiliarity with the surveyor also seemed to generate a certain level of reluctance.
Certainly, during a tracer conducted for accreditation, the surveyor is unfamiliar to staff,
however, during a process improvement project, the importance of establishing trust was
underscored. Care must also be taken to ensure questions are perceived as assessing the process
or program and not the provider. The intent of the tracer is to evaluate the ASP program,
therefore, staff should not be made to feel as though their knowledge or the quality of care they
provide is being questioned.
The greatest potential barrier to completion of tracers is the time required to complete a
tracer for the surveyor and those being interviewed. The tracer needed to be conducted on the
third day of patient care as required by questions regarding review of antibiotics. This
requirement presented a challenge with regards to scheduling. The surveyor may not be able to
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conduct tracers on site daily and the prescriber may not be available several days later. However,
this challenge can potentially be mitigated if the surveyor is able to access the patient chart
remotely, thus, providing the opportunity to review the chart off site. Additionally, while not
ideal, interviews with prescribers, nurses, and clinical pharmacists can be conducted via
telephone. The ability to conduct phone interviews provides flexibility to both the surveyor and
the healthcare professional being interviewed.
While the interview portion of the tracer offers valuable insight into the general
knowledge of antimicrobial stewardship and the ASP program at the hospital, it may be more
efficient to obtain the information in a questionnaire or survey and save only select questions,
particularly those that require demonstrations for the in-person interview. North et al. (2009)
discuss the value of utilizing an e-survey to address areas identified in a tracer that require
follow-up. The authors state that an e-survey can either assess the extent of a particular standard
knowledge gap or provide information about a gap area. E-surveys are able to complement tracer
methodology by expanding the range of assessment of standard knowledge, much like the
intention of the interview portion of the tracer that was implemented (North et al., 2009). Given
the limited time staff members have to answer questions, completing the interview portion at a
time separate from the tracer questions may decrease the burden on staff. Additionally, the
ability to reach staff in multiple departments may help to increase the scope of the tracer and
increase understanding of stewardship practices within different departments of the hospital. For
example, many, if not all, patients admitted with CAP start in the Emergency Department which
is often where they receive their first dose of antibiotics. The surveyor noted that Emergency
Department physicians seemed to have a preference for which empiric therapy they prescribed
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which differed from hospitalists’ preferences, however, the tracer was not equipped to capture
such a difference.
Administering an anonymous e-survey may encourage staff to provide more thoughtful,
candid answers, however encouraging participation may be difficult and the ability to correlate
individual answers to practice would be forfeited. North et al. (2009) also note e-surveys are able
to determine baseline knowledge and then assess and quantify improvement in knowledge over
time. Since tracers can be used as an opportunity for education, the ASP team may find it
interesting to assess any changes in knowledge and practice related to modifications or additions
to the hospital ASP.
Conclusions
Ultimately the question remains whether tracer methodology can be implemented to
assess a hospital ASP. Hospital ASPs are multifaceted as they must incorporate numerous
components including staff education, interventions to improve antibiotic use, pharmacy
expertise, and tracking and reporting (CDC, 2019d) and target multiple disciplines. However,
much of the onus falls to the physicians or other advanced practice providers (APPs) responsible
for assessing and determining the appropriate treatment plan for patients. A successful tracer
demonstrates whether certain actions are occurring, but it may be difficult to apply tracer
methodology to educe the reasons why certain actions are or are not occurring. The goal of many
ASP interventions regarding education and feedback, is to influence the internal processes of
providers and enhance the quality of patient care. In the instance of CAP, assessing the type of
empiric antibiotic therapy ordered upon initial diagnosis is straightforward, however, the internal
processes used by the practitioner, such as reasons for ordering certain diagnostics or
determining the severity of a patient’s condition, are more difficult to capture objectively.
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The implemented tracer provided insight into the progression of patient care upon
admission from the ED to the hospital and revealed the complex manner in which patient care
progresses after the initial admission. Tracer methodology can be applied to assessing various
components of an ASP, but it must be understood that an interpretation of the results is not
necessarily straightforward. Tracer questions should be specific to ensure clarity in the results,
however, specific questions may prompt providers, therefore jeopardizing organic answers. If
used by an accrediting body to evaluate an ASP, care must be taken that results are not
interpreted too narrowly, unless questions have been tested and found to elicit answers with no
other explanation.
The implementation of a tracer to evaluate a hospital ASP has the potential to provide
constructive feedback to the ASP team regarding successful interventions, as well as identify
potential gaps or deviations from evidence-based practices. The portion of the tracer that seeks to
ascertain the knowledge of clinicians regarding general antibiotic stewardship and the ASP
within the hospital will provide valuable information when compared to information collected
from the patient chart related to antimicrobial prescribing practices. The purpose of this ASP
tracer was not to be punitive in any way. Therefore, regardless of the results, sharing the results
with hospital leadership and employees can provide valuable education, especially if presented
with transparency. Requesting feedback from all stakeholders will aid in the development and
implementation of new interventions aimed at addressing the issues uncovered.
Once the tracer has been successfully implemented, future tracers can be conducted to
evaluate whether the initial tracer had an impact on clinicians with regards to antimicrobial
prescribing. However, future tracers will require updates to account for interventions
implemented as a result of previous tracers. The same process implemented to create and
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conduct the original tracer can be utilized. Additional research may be needed if new standards
or guidelines are available, and new questions should be added to account for interventions
implemented as a result of information gathered from the first tracer. Also, the potential for
accrediting agencies to implement tracers to evaluate ASPs remains a possibility, thus, future
tracers can also be modified to better reflect feedback received from such institutions.
If a tracer can successfully be created and implemented to evaluate a hospital ASP, then
applying the method to evaluate ASPs in outpatient and long-term care facilities should also be
considered, as antimicrobial stewardship recommendations exist for these institutions which are
also subject to review from TJC and CMS (CDC, 2015; CMS, 2016; Sanchez et al., 2016; TJC,
2019). According to the CDC, approximately half of antibiotics prescribed in the outpatient
setting are inappropriate (Sanchez, et al., 2016). Ross et al. (2017) and Wisdom et al. (2012)
demonstrate that tracer methodology can successfully be applied to the outpatient setting. Thus,
it would be reasonable to apply tracer methodology to evaluate fulfillment of the core elements
of outpatient antibiotic stewardship and the core elements of nursing home antibiotic
stewardship.
The ability of tracers to help hospitals not only identify potential deficiencies, but the
reasons contributing to deviations from evidence-based practices provides healthcare settings
with a potentially invaluable evaluation tool. The existence of such explanatory evaluation tools
is important when designing and creating education and interventions aimed at helping
healthcare professionals provide quality, evidence-based patient care.
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Appendix A
Letter of Support from Agency

2200 River Plaza Drive
Sacramento, CA 95833

June 22, 2020
June 22, 2020

To Whom It May Concern,

To Whom It May
Concern,

This is a letter of support for Christine Smyth to implement her DNP Comprehensive Project: Utilizing
This is a letter of support
Tracer Methodology to Evaluate the Effectiveness of a Hospital Antimicrobial Stewardship Program
for Christine Smyth to
within the Sutter Health System, conducted primarily at Eden Medical Center, Castro Valley, California.
implement her DNP
Comprehensive Project:
Utilizing Tracer
Methodology
to Evaluate
I will be acting as a co-mentor providing Christine with antimicrobial stewardship
and pharmacological
the Effectiveness of a
therapies guidance related to this project.
Hospital Antimicrobial
Stewardship Program
within the Sutter Health
Sincerely,
System, conducted
primarily at Eden
Medical Center, Castro
Valley, California.
Lisa Hammer Rieg, PharmD, FCSHP, FASHP
Clinical Coordinator, Drug Use Management and Infectious Diseases Clinical Programs
Sutter Office of System Enterprise, Pharmacy
2200 River Plaza Drive
Sacramento, CA 95833
Cell: (916) 210-9546

I will be acting as a comentor providing
Christine with
antimicrobial
stewardship and
pharmacological
therapies guidance
related to this project.

Sincerely,

Lisa Hammer Rieg,
PharmD, FCSHP, FASHP
Clinical Coordinator, Drug Use
Management and Infectious
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Appendix B
Non-Research Evidence Appraisal Tool

Citation

Conceptual
Framework

Design/
Method

Sample/
Setting

Bailey, C.,
Kay, R.,
Starling, P.,
Walsh, K.,
Samuel, V.,
. . .Murray,
K. (2015).
A health
system’s
approach to
successful
accreditatio
n utilizing
joint
commissio
n’s
infection
control
tracer
methodolo
gy. Poster
Abstracts.
American
Journal of
Infection
Control,
43, S18-73.

Not specified

- Utilization
of the Joint
Commission
Tracer
methodolog
y to improve
ongoing
readiness
and
compliance
with
national
standards
for each
Joint
Commission
Chapter
-Utilized a
Joint
Commission
Resource
Consultant
to train staff
to conduct
Infection
Control
tracers

Health
system: five
acute care
facilities,
multiple
outpatient
facilities and
clinics

Variables
Studied and
Their
Definitions
-Readiness and
compliance
with national
standards
-system
processes

Measurement

Tracers and
audits utilizing
Joint
Commission
Tracer
methodology

Data
Analysis

Not
specified

Findings

-Employees improved navigation of
electronic medical record based on
use of tracer methodology
-Increased staff confidence led to:
-improved quality of
information presented to
surveyors
-improved compliance to key
infection control standards
-development of system-wide
consistency

Appraisal:
Worth to
Practice
*Level V, A
Strengths:
Leadership
devoted
resources and
specific time for
staff to focus on
compliance
standards (e.g.
“no-meeting
Wednesdays”
Limitations:
Project based on
input from
consultant;
implementation
described as
“challenging”

*Johns Hopkins Hospital/The Johns Hopkins University (2017). Appendix F: Non-Research evidence appraisal tool. Retrieved from https://www.hopkinsmedicine.org/evidencebased-practice/_docs/appendix_f_nonresearch_evidence_appraisal_tool.pdf
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Citation

Bookbinder
, M.
Hugodot,
A.,
Freeman,
K., Homel,
P.,
Santiago,
E., Riggs,
A., . .
.Portenoy,
R. K.
(2018).
Developme
nt and field
test of an
audit tool
and tracer
methodolo
gy for
clinician
assessment
of quality
in end-oflife care.
Journal of
Pain and
Symptom
Manageme
nt, 55(2),
207-216.

Conceptual
Framework

Not
specified

Design/
Method

Sample/
Setting

-tracer
methodology
-large pool of
questions
collected into
three
instruments
used in
prospective
survey of care
-survey
included
reviews of
medical
record and
interviews
with
physicians,
nurses, social
workers, or
chaplain who
provided care
during 48 hrs
preceding
patient death

-Prospective
survey
conducted at
Beth Israel
Medical
Center
(urban
teaching
hospital),
145 deaths
evaluated
from
inpatient
palliative
care unit,
medical
intensive
care unit, or
one of seven
medical
units
-Field test:
127 dying
patients
during 48
hours prior
to death

Variables
Studied and
Their
Definitions
-Overall family
-Overall
patient
-After death
-Last hours
-Psychosocial
-Religion
-Tradition
-Decision
making
Communicatio
n
-Symptom
control
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Measurement

-Professional
Caregiver
Interview Tool:
155 items
-Global
Assessment Tool
for Physicians: 32
items
Chart Audit Tool:
51 items

Data Analysis

-Factor
analysis
-canonical
correlation
-group
comparisons

Findings

-Small number of items
could be used to validly
capture items

Appraisal: Worth
to Practice

*Level V, A
Strengths:
provider
cooperation;
acceptable
administration
burden;
nonthreatening to
staff; able to
identify and
broadly
characterize quality
concerns in
individual groups
of patients
Limitations:
-sample size, too
much missing data
to include in factor
analyses; physician
data too
imcomplete; family
and patient
assessments not
included; symptom
control excluded
from canonical
correlation; data
not normally
distributed;

*Johns Hopkins Hospital/The Johns Hopkins University (2017). Appendix F: Non-Research evidence appraisal tool. Retrieved from https://www.hopkinsmedicine.org/evidencebased-practice/_docs/appendix_f_nonresearch_evidence_appraisal_tool.pdf
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Citation

Ross, A.,
Feider, L.,
Nahm, ES., &
Staggers,
N. (2017).
An
outpatient
improveme
nt project:
A baseline
assessment
of
adherence
to pain
reassessme
nt
standards.
Military
Medicine,
182(5/6),
e16881695.

Conceptual
Framework

Situation
Awareness
framework

Design/
Method

Sample/
Setting

-Electronic
Medical
Record query
-observation of
clinic
workflow using
tracer
methodology
-evaluation of
clinic
documentation
-

-Large military
outpatient
clinic
- patients who
received
Toradol
between Feb 1May30, 2013
-for
observation:
convenience
sample of 12
patients

Variables
Studied and
Their
Definitions
-pain
reassessment
compliance
rates (pain
intensity scale,
met time
requirement,
location of
pain, side
effects of med,
patient
education,
overall)
-associated
documentation
-clinic
workflow
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Measurement

-workflow
questionnaire
-workflow
observation

Data
Analysis

Findings

Workflow
analysis

--clinic staff impacted by lack of
standardized procedures and
heavy reliance on staff memory
-three distinct workflow processes
identified: exam room, treatment
room, examination room to
treatment room
-staff nurses perform one of three
roles: triage nurse, nurse assigned
to a provider or exam room, nurse
assigned to the treatment room
-nurses administering medications
had to continually assess patients
in multiple locations while also
rotating patients through exam
rooms
-documentation could occur with
computers in multiple rooms
-nurse administering medication
had several steps to complete
-workflow did not allow or
allowed only limited information
exchange about patients moving
from exam to treatment room. No
formalized handoff procedure.

Appraisal: Worth to
Practice

*Level V, A
Strengths:
-small tracer sample
size allowed thorough
evaluations of pain
reassessment
practices
-strong leadership
support
-team members
identified early in
project
Limitations:
-only one large
primary care clinic
-Military’s current
EMR may not be
generalizable to other
populations and
settings
-small tracer sample
size limits
generalizaof findings
-clinic relocated in
middle of project,
thus changing
workflows

*Johns Hopkins Hospital/The Johns Hopkins University (2017). Appendix F: Non-Research evidence appraisal tool. Retrieved from https://www.hopkinsmedicine.org/evidencebased-practice/_docs/appendix_f_nonresearch_evidence_appraisal_tool.pdf
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Citation

Wisdom, J.
P., Knapik,
S., Holley,
M. W., Van
Bramer, J.,
Sederer, L.
I., &
Essock, S.
M. (2012).
New
York’s
outpatient
mental
health
clinic
licensing
reform:
Using
tracer
methodolo
gy to
improve
service
quality.
Psychiatric
Services,
63(5), 418420.

Conceptual
Framework

Not
specified

Design/
Method

-tracer
methodology
-licensing
instrument
-interviews

Sample/
Setting

-11 clinics (2-3
clinics from
each region of
New York, mix
of non-forprofit, county,
hospital-based,
and state
operated
clinics serving
adults, children
and
adolescents,
and adults and
children)

Variables
Studied and
Their
Definitions
-current clinic
functioning
-systems
providing care
-experience of
services for
people with
serious mental
illness and
their families
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Measurement

Data Analysis

Not specified

percentage

Findings

- five of 11 clinics
received operating
license with new
process for fewer
months than previous
licensing process
-providers found to be
reluctant to share
information about
service users with other
providers
-new process more
focused

Appraisal: Worth
to Practice

*Level V, A
Strengths: key
collaborations
contributed to
success of tracer
development;
positive perception
of technique as
OMH survey team
and clinic staff
reported a more
positive licensing
process

Limitations:
challenge to
continuously
incorporate
feedback from
clients and
providers; ensuring
consistency among
OMH surveyors;
process will require
continued updating

*Johns Hopkins Hospital/The Johns Hopkins University (2017). Appendix F: Non-Research evidence appraisal tool. Retrieved from https://www.hopkinsmedicine.org/evidencebased-practice/_docs/appendix_f_nonresearch_evidence_appraisal_tool.pdf
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Appendix C
Gap Analysis

•
•

•

Current State
Existing ASP
Evaluation of stewardship practices include:
audit and feedback, rates of usage of
specific antibiotics, prescribing rates of
individual prescribers

Gap
Tracer to evaluate antimicrobial prescribing
practices and barriers to AS does not exist

•

Desired State
Tracer to determine current antimicrobial
prescribing practices when treating CAP and
identify barriers to AS

Action Plan
Plan
•

Establish multidisciplinary team to develop
tracer
• Designate surveyors to conduct tracer,
provide training/education
• Create tracer based on CDC’s Core Elements
of Hospital Antibiotic Stewardship Programs,
TJC’s New Antimicrobial Stewardship
Standards, and the American Thoracic
Society’s guidelines for diagnosing and
treating adults with CAP
Conduct
• Surveyor to begin conducting tracer
Analyze
• Data to be analyzed
• Qualitative results to be compared to
quantitative data relating to antimicrobial
prescribing practices
Share
• Results to be shared with hospital
leadership, ASP team, and survey
participants
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Appendix D
Work Breakdown Structure
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Appendix E
Gantt Chart
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Appendix F
Tracer Tool
Antimicrobial Stewardship Program Tracer
Purpose: Assess and/or validate organizational Antimicrobial Stewardship Program (ASP);
identify potential gaps or deviations from evidence-based practices and internal/external
guidelines; identify obstacles to Antimicrobial Stewardship (AMS); educate/inform physicians,
advanced practice providers (APPs), and nurses regarding appropriate antibiotic prescribing
practices
Interviewee: Hospitalist, APP, attending of record for patient admitted to the hospital, nurses,
pharmacists
For Physicians and APPs:
Factors influencing prescribing (Action): patient specific
1) Prior to today, were you aware of your hospital having an antimicrobial stewardship
program (ASP)? ☐ yes ☐ no ☐ unsure
2) If YES to #2, do you know who the ASP leaders are at your hospital/institution?
☐ yes ☐ no
3) Do you think you have adequate knowledge on the treatment of pneumonia to choose
empiric antibiotic therapy?
☐ yes ☐ no
4) What resources do you use when needed when choosing empiric antimicrobial therapy?
(Examples could include: institution specific clinical guidelines, institution specific order
sets, national guidelines, utilize the hospital antibiogram, UpToDate, etc.)
•

If hospital-specific guidelines or an antibiogram, ask provider to
demonstrate how the information is accessed (e.g. pocket cards, online,
etc.)

•

When was the last time provider accessed guidelines or received education
regarding antimicrobial therapy?
•

How was the education delivered?
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5) How do you determine a definitive antimicrobial regimen (including duration) for your
patients diagnosed with a microbiologically confirmed infection?
(Examples could include: institution specific clinical guidelines, national guidelines,
UpToDate, etc., duration’ response may be based on clinical improvement)
6) [If not addressed above] Does your hospital have hospital-specific guidelines for any
common infections? ☐ yes ☐ no
a. If YES, can you please demonstrate where to find them?
7) Does your hospital implement any specific antimicrobial stewardship (AS) interventions?
(preauthorization, prospective audit and feedback? Infection-specific order sets?
Diagnostic stewardship) ☐ yes ☐ no
a. Can you specify interventions or give examples of previous interventions?
8) Who do you contact to ask questions regarding antimicrobial prescribing? (Examples
could include floor pharmacists, ASP, colleagues.)
a. How would you contact these individuals?
9) Do you find the resources available to you adequate? ☐ yes ☐ no
Education:
10) Do you receive education from your hospital regarding antimicrobial stewardship and the
optimization of antibiotics? ☐ yes ☐ no
11) If answer to #10 is YES, how is education delivered? (Examples: prospective audit and
feedback? Handshake stewardship? Rounding? Newsletters? One on one consult with
ASP team or with stewardship pharmacist or ID physician? Lectures? Electronic chart
updates?)
12) What education do you provide the patient when starting them/discharging them on an
antimicrobial? (Examples: adverse reactions, antibiotic resistance, optimal prescribing;
verbal education, handouts, posters; assessment of patient understanding?)
Tracking and Reporting:
13) Do you receive data regarding antimicrobial prescribing at your hospital? ☐ yes ☐ no
14) If answer to #13 is YES, what type of data? (Examples: antibiotic utilization, duration of
antibiotic therapy; outcomes measurements- e.g. resistance patterns, C. difficile infection
rates impact of AMS interventions)

How is data delivered and in what format? (provider specific, service-line specific,
hospital-wide)
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Infection Specific Questions- Pneumonia
Dx:
Patient tracer (medical record):
1) Orders placed from order set? ☐ yes ☐ no
2) How did you determine patient’s severity of pneumonia?
3) Is the following documented in the patient chart?
• Diagnostic criteria documented?
One or more major criterion OR ≥ three minor criterion
Major criteria
☐ Septic shock with need for vasopressors
☐ Respiratory failure requiring mechanical ventilation
Minor criteria
☐ Respiratory rate ≥ 30 breaths/min
☐ PaO2/FIO2 ratio ≤ 250
☐ Multilobar infiltrates
☐ Confusion/disorientation
☐ Uremia (blood urea nitrogen level ≥ 20mg/dl)
☐ Leukopenia (r/t infection alone) (white blood cell count < 4,000 cells/μl)
☐ Thrombocytopenia (platelet count < 100,000/ μl)
☐ Hypothermia (core temp < 36°C)
☐ Hypotension requiring aggressive fluid resuscitation

Classified as Severe Pneumonia ☐
Classified as Non-severe Pneumonia ☐
4) Did you decide or verify if the patient has risk factors for MRSA, P. aeruginosa, or other
MDROs?
☐ yes ☐ no
If YES, how?
☐ prior isolation of P. aeruginosa
☐ prior isolation of MRSA
☐ recent hospitalization and exposure to parenteral antibiotics
☐ arrived from facility with known MDROs
5) Pretreatment gram stain and culture of lower respiratory secretions ordered?
☐ yes ☐ no
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If YES, how did you determine if sputum culture should be ordered?
☐ classified as severe CAP (especially if intubated)
☐ being empirically treated for MRSA or P. aeruginosa
☐ previous infection with MRSA or P. aeruginosa (especially prior respiratory
infection)
☐ hospitalized and received parenteral antibiotics (during hospitalization or not)
in last 90 days
☐ arrived from facility with known MDROs
Non-Severe Pneumonia
1) How did you decide on your treatment for non-severe CAP?
2) Standard empiric treatment for non-severe CAP used? ☐ yes ☐ no
If YES, antibiotic therapy prescribed:
For non-severe CAP without MRSA or P. aeruginosa risk factors:
☐ Combination therapy with β-Lactam (ceftriaxone 1 -2g daily) and a
macrolide (azithromycin 500 mg daily)
☐ Monotherapy with a respiratory fluoroquinolone (levofloxacin 750 mg
daily) (less preferred due to FQN safety issues; use if beta-lactam to be
avoided)
☐ β-Lactam (see above) and doxycycline 100 mg twice
☐ none
For non-severe CAP with MRSA or P. aeruginosa risk factors:
☐ Empiric therapy for MRSA: vancomycin 15mg/kg q 12 hours and βLactam (ceftriaxone 1-2g daily) and macrolide (azithromycin 500 mg
daily) or doxycycline 100mg bid
☐ Empiric therapy for P. aeruginosa: piperacillin-tazobactam 4.5g q 6 or
q 8 hours or cefepime 2g q 8 hours or aztreonam 2g q 8 hours (only for
severe β-Lactam allergies), or meropenem 1g q 8 hours and macrolide
(azithromycin 500 mg daily); or doxycycline 100 mg q12 hours
☐ none of the above
3) Is Vancomycin to be administered? ☐ yes ☐ no
a. If YES, was MRSA PCR ordered? ☐ yes ☐ no
b. If YES, was MRSA PCR collected prior to Vancomycin administration or within
24 hours of first dose? ☐ yes ☐ no
4) If PCR negative, was Vancomycin discontinued? ☐ yes ☐ no
If NO, why?
5) If PCR positive, Vancomycin continued? ☐ yes ☐ no
If YES, why?
6) If patient being treated for P. aeruginosa, was sputum culture ordered? ☐ yes ☐ no
a. If YES, was sputum culture collected prior to antibiotic initiation? ☐ yes ☐ no
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7) Did provider adjust antibiotics based on culture results? ☐ yes ☐ no
Severe Pneumonia
1) How did you decide on your treatment for severe CAP?
2) Standard empiric treatment for severe CAP used? ☐ yes ☐ no
If YES, antibiotic therapy prescribed:
For severe CAP without MRSA or P. aeruginosa risk factors:
☐ Combination therapy with β-Lactam (ceftriaxone 1 -2g daily) and a
macrolide (azithromycin 500 mg daily)
☐ β-Lactam/fluoroquinolone
☐ β-Lactam (see above) and doxycycline 100 mg twice daily
☐ none of the above
For severe CAP with MRSA or P. aeruginosa risk factors:
☐ Empiric therapy for MRSA: vancomycin 15mg/kg q 12 hours and βLactam (ceftriaxone 1-2g daily) and macrolide (azithromycin 500 mg
daily)
☐ Empiric therapy for P. aeruginosa: piperacillin-tazobactam 4.5g q 6 or
q 8 hours or cefepime 2g q 8 hours or aztreonam 2g q 8 hours (only for
severe β-Lactam allergies), or meropenem 1g q 8 hours and macrolide
(azithromycin 500 mg daily) or doxycycline 100 mg q12 hours
☐ none of the above
6) Is Vancomycin to be administered? ☐ yes ☐ no
a. If YES, was MRSA PCR ordered? ☐ yes ☐ no
b. If YES, was MRSA PCR collected prior to Vancomycin administration or within
24 hours of first dose? ☐ yes ☐ no
7) If PCR negative, was Vancomycin discontinued? ☐ yes ☐ no
If NO, why?
8) If PCR positive, Vancomycin continued? ☐ yes ☐ no
If YES, why?
9) If patient being treated for P. aeruginosa, was sputum culture ordered? ☐ yes ☐ no
a. If YES, was sputum culture collected prior to antibiotic initiation? ☐ yes ☐ no
10) Did provider adjust antibiotics based on culture results? ☐ yes ☐ no
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All Pneumonia
Patient tested for influenza? ☐ yes ☐ no
Patient urine tested for Legionella antigen? ☐ yes ☐ no
Patient urine tested for pneumococcal antigen? ☐ yes ☐ no
Serum procalcitonin level ordered prior to initiation of antibiotics or prior to second
dose of antibiotics? ☐ yes ☐ no
5) Aspiration pneumonia? ☐ yes ☐ no
a. If YES, additional anaerobic coverage beyond standard empiric treatment for CAP?
☐ yes ☐ no
a. If YES, is a lung abscess or empyema suspected? ☐ yes ☐ no
Note: Metronidazole is most commonly used for anaerobic coverage. Meropenem and
piperacillin-tazobactam also have anaerobic coverage.
1)
2)
3)
4)

6) Does antibiotic order include:
☐ indication
☐ expected duration
7) Documentation for antibiotic timeout (if done at this institution, remember terminology
is hospital specific, what terminology is used? Handshake stewardship? Rounds?)
☐ Will infection respond to antibiotics?
☐ Have proper cultures and diagnostic tests been performed? (sputum culture, blood
culture; possible diagnostic tests: pneumococcal urinary antigen, legionella urinary
antigen, influenza during season, MRSA screen by PCR)
☐ Can antibiotics be stopped or improved by narrowing spectrum or changing from IV
to oral? (de-escalation)
☐ Duration of therapy (hospital stay + post-discharge therapy)
☐Was there an intervention by ASP team?
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For nurses:
Action:
1) Prior to today were aware that your hospital has an antimicrobial stewardship program
(ASP)?
☐ yes ☐ no ☐ unsure
2) If YES to #1, do you know who the ASP leaders are at your hospital/institution?
☐ yes ☐ no
3) Are you provided with education regarding appropriate indications to obtain cultures?
☐ yes ☐ no
4) Are you provided with education regarding proper specimen collection techniques to
reduce contamination? ☐ yes ☐ no
5) Are you provided with education regarding antibiotic resistance and adverse reactions
from antibiotics? ☐ yes ☐ no
6) Are you comfortable initiating discussions with patients’ care teams regarding the
transition from IV to oral antibiotics when the patient is able to tolerate oral medication?
☐ yes ☐ no
7) Are you comfortable prompting antibiotic reviews with patients’ care teams?
☐ yes ☐ no
If YES, when is it appropriate to initiate such reviews?
8) Does your facility have specific interventions to ensure optimal use of antibiotics for
treating the most common infections in hospitals? (e.g. ensuring correct discharge
duration of therapy?) ☐ yes ☐ no
9) If answer to #6 is YES, can you provide examples?

Education
10) Do you receive education from your hospital regarding antimicrobial stewardship and the
optimization of antibiotics? ☐ yes ☐ no
11) If answer to #10 is YES, how is education delivered? (Newsletters? Lectures? Electronic
chart updates?)
12) What education do you provide the patient when starting them/discharging them on an
antimicrobial? (adverse reactions, antibiotic resistance, optimal prescribing; verbal
education, handouts; posters; assessment of patient understanding?)
13) Are nurses involved in creating educational materials at your hospital?
☐ yes ☐ no ☐ unsure
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Tracking and Reporting:
14) Do you receive data regarding antimicrobial prescribing at your hospital? ☐ yes ☐ no
15) If answer to #14 is YES, what type of data? (antibiotic prescribing utilization; outcomes
measurements- e.g. resistance patterns, C. difficile; impact of ASP interventions)
a.

How is data delivered and in what format? (provider specific, service-line
specific, hospital-wide)

Patient Specific Questions:
16) Are you aware of risk factors for MRSA? ☐ yes ☐ no
a. If YES, is this patient at risk for MRSA? ☐ yes ☐ no ☐ don’t know
b. If YES, was a nasal PCR collected? ☐ yes ☐ no
c. If YES, has the final result been reviewed? ☐ yes ☐ no ☐ not available
17) Are you aware of risk factors for P. aeruginosa? ☐ yes ☐ no
a. If YES, do you know if this patient is at risk for P. aeruginosa
☐ yes ☐ no ☐ don’t know
b. If YES, was a sputum sample collected? ☐ yes ☐ no
If YES, has the final result been reviewed? ☐ yes ☐ no ☐ not available
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For clinical pharmacists:
Action:
1) Do you think you have adequate knowledge of the treatment of pneumonia to evaluate
empiric antibiotic therapy?
☐ yes ☐ no
2) What resources do you use when evaluating whether a chosen antimicrobial therapy is
appropriate?
3) Do you have specific experience with antibiotic stewardships?
☐ yes ☐ no
4) Does your hospital have a pharmacist(s) responsible for leading implementation efforts to
improve antibiotic use?
☐ yes ☐ no
5) Does your hospital pharmacy have a process in place to review antibiotics prescribed?
☐ yes ☐ no
6) If answer to #5 is YES, is this done/documented within 48-72 hours of initiation of
antibiotic therapy?
Does the process include the following?
☐ Review for dose adjustments as needed? (e.g. in cases of organ dysfunction or
therapeutic drug monitoring)
☐ Review for dose optimization (e.g. in cases of extended -infusion
administration of beta-lactams in critically-ill patients and those infected with
drug-resistant organisms)
☐ Alerts for duplicative therapies (e.g. simultaneous use of multiple agents with
overlapping spectra)
☐ Automatic changes from intravenous to oral antibiotic therapy
☐ Time-sensitive automatic stop orders
☐ Detection and prevention of antibiotic-related drug-drug interactions
Education:
7) Do you receive specific education/training regarding antibiotic stewardship at your
hospital? ☐ yes ☐ no
8) IF answer to #7 is YES, how is education/training delivered ? (posters, formal training,
certificate program?)
9) Do you receive data regarding antimicrobial prescribing at your hospital? ☐ yes ☐ no
10) If answer to #9 is YES, what type of data is shared? (rate of antibiotic prescribing;
outcomes measurements- e.g. resistance patterns, C. difficile; impact of ASP
interventions)
a.

How is data delivered and in what format? (provider specific, service-line
specific, hospital-wide)
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Patient Specific:
11) Did you decide or verify if the patient has risk factors for MRSA, P. aeruginosa, or other
MDROs?
☐ yes ☐ no
If YES, what criteria did you use?
☐ prior isolation of P. aeruginosa
☐ prior isolation of MRSA
☐ recent hospitalization and exposure to parenteral antibiotics
☐ arrived from facility with known MDROs
12) Is Vancomycin to be administered? ☐ yes ☐ no
a. If YES, was MRSA PCR ordered? ☐ yes ☐ no
b. If YES, was MRSA PCR collected prior to Vancomycin administration or within
24 hours of first dose? ☐ yes ☐ no
c. If YES, has the final result been reviewed? ☐ yes ☐ no ☐ not available
d. If PCR negative, was Vancomycin discontinued? ☐ yes ☐ no
If NO, why?
e. If PCR positive, Vancomycin continued? ☐ yes ☐ no
Is YES, why?
13) Is patient being treated for P. aeruginosa? ☐ yes ☐ no
a. If YES, was sputum culture ordered? ☐ yes ☐ no
b. If YES, was sputum culture collected prior to antibiotic initiation? ☐ yes ☐ no
c. If YES, has the final result been reviewed? ☐ yes ☐ no ☐ not available
14) On calendar day three, was antibiotic therapy discussed? ☐ yes ☐ no
15) Was a decision made to change antibiotics? ☐ yes ☐ no
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Appendix G
Tracer Toolkit
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Appendix H
Responsibility/Communication Plan

Facilitation

Innovation

Recipients

Context

Novice-DNP
student

-Problem Identification: ASP
evaluation
-Review/appraisal of evidence
-Develop tracer
-Present process of implementing
tracer
-Provide guidelines to implement
and sustain tracer within system

-Establish understanding of organizational
priorities
-Establish understanding of accreditation
requirements
-Establish understanding of influence and
requirements of California Department of
Public Health

Experiencedadministrative
nursing
director and a
regional
clinical
coordinator
pharmacist
Expertmedical
director of
pharmacy and
infection
control

-Help novice establish access to
EMR and contact with clinical staff
to implement tracer
-Orient/onboard novice

-Initiate tracer team meetings via face to face meetings
and Skype
-Create tracer with input feedback from stakeholders
-Establish relationships with key stakeholders
-Introduce tracer project to staff via email
-Explain reason for tracer to leadership and clinical staff
as needed during rounds or tracer
-Conduct tracer interviews with hospitalists,
pharmacists, nurses in person and via telephone
-Present tracer findings to ASP team, hospita l
leadership, and staff
-Facilitate communication between novice facilitator
and leadership/management via face to face meetings
and email

-Facilitate communication between novice facilitator
and leadership/management via face to face meetings
and email

-Introduce innovation to hospital leadership
-Integrate innovation into ASP
-Facilitate the communication of results to
leadership and staff

-Provide feedback/mentoring to
novice during tracer development
-Review final draft of tracer prior to
implementation
-Aid in refining and improving
tracer as needed
-Evaluate final outcome of tracer
-Facilitate integration of tracer
methodology into future evaluation
process

-Positively promote the innovation to
stakeholders
-Provide formal and informal leadership
support of project by aiding novice facilitator
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Appendix J
Budget and Break-Even Analysis
Year One

Position

Number of
FTE

Number of
Hours
Required

Annual
Salary

Hourly Rate

Medical Director of Pharmacy
and Infectious Disease

NA

20

$210,000

$101

$2,019

Clinical Coordinator Pharmacist,
Formulary Management and Clinical Practice
DNP student if paid

NA

20

$136,000

$65

$1,308

0.13

NA

$98,000

$47

$12,740

Total Cost

$16,067

# of patients to
break even

Total
Cost

12
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Appendix K
Statement of Non-Research Determination

Doctor of Nursing Practice
Statement of Non-Research Determination (SOD) Form
The SOD should be completed in NURS 7005 and NURS 791E/P or NURS 749/A/E

General Information
Last Name:

Smyth

CWID Number:
Course Name &
Number:

First Name:

Christine

Semester/Year:

Spring 2020

Advisor Name:

Dr. Wanda Borges

NURS 749B

Chairperson
Name:

Project Description
1. Title of Project

Utilizing Tracer Methodology to Evaluate the Effectiveness of a Hospital Antimicrobial Stewardship
Program
2. Brief Description of Project
Clearly state the purpose of the project and the problem statement in 250 words or less.

The purpose of the project is to evaluate the success of a hospital antibiotic stewardship program, identify
potential gaps in knowledge or deviations from evidence-based practices, and verify the fulfillment of
accreditation requirements utilizing tracer methodology.
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3. AIM Statement: What are you trying to accomplish?
The goal of this project is to utilize tracer methodology to assess the ef f ectiveness of a hospital antibiotic
stewardship interventions by August 2020, through the evaluation of healthcare providers’ awarene ss of antibiotic
stewardship within their institution, knowledge regarding antimicrobial stewardship components, and approach to
treating patients with community acquired pneumonia (CAP).
4 Brief Description of Intervention (150 words).

The intervention begins with developing a tracer based on the CDC’s Core Elements of Hospital
Antibiotic Stewardship Programs: 2019, TJC’s New Antimicrobial Stewardship Standards, and the
American Thoracic Society’s guidelines for diagnosing and treating adults with CAP . The tracer will
then be conducted in a hospital setting by reviewing the charts of at least 30 patients diagnosed with CAP
and interviewing physicians, APPs, clinical pharmacists, and nurses involved in the patient’s care. The results
of the tracer will be analyzed and reported to the hospital antimicrobial stewardship program for the
4a. How will this intervention be implemented?
• Where will you implement the project?
•

Attach a letter f rom the agency with approval of your project.

•

Who is the f ocus of the intervention?

•

How will you inf orm stakeholders/participants about the project and the intervention?

The tracer will be conducted at Eden Medical Center. The focus of the intervention is to evaluate the
hospital Antibiotic Stewardship Program by interviewing hospitalists, APPs, clinical pharmacists, and nurse
practitioners caring for patients with CAP and reviewing the EMR of patients being treated for CAP.
Stakeholders of the project intervention will be informed via email and face to face meetings (attending
patient rounds, ASP meetings)

5. Outcome measurements: How will you know that a change is an improvement?
• Measurement over time is essential to QI. Measures can be outcome, process, or balancing measures.
Baseline or benchmark data are needed to show improvement.
•

Align your measure with your problem statement and aim.

•

Try to def ine your measure as a numerato r/denominator.
o What is the reliability and validity of the measure? Provide any tools that you will use as
appendices.
o

Describe how you will protect participant conf identiality.

Using the developed tracer, the outcome measures will include physician and APP knowledge of
hospital ASP; nurse knowledge of hospital ASP; clinical pharmacist knowledge of hospital ASP;
physician and APP self-reported confidence regarding pneumonia treatment; and compliance
with ATS treatment guidelines for CAP
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DNP Statement of Determination
Evidence-Based Change of Practice Project Checklist*
The SOD should be completed in NURS 7005 and NURS 791E/P or NURS 749/A/E

Project Title:
Utilizing Tracer Methodology to Evaluate the Ef f ectiveness of a Hospital Antibiotic S tewardship Program

Mark an “X” under “Yes” or “No” for each of the following statements:

Yes

The aim of the project is to improve the process or delivery of care with established/ accepted
standards, or to implement evidence-based change. There is no intention of using the data f or
research purposes.

X

The specif ic aim is to improve perf ormance on a specif ic service or program and is a part of
usual care. All participants will receive standard of care.

X

The project is not designed to f ollow a research design, e.g., hypothesis testing or group
comparison, randomization, control groups, prospective comparison groups, cross -sectional, case
control). The project does not f ollow a protocol that overrides clinical decision-making.

X

The project involves implementation of established and tested quality standards and/or systematic
monitoring, assessment or evaluation of the organization to ensure that existing quality standards
are being met. The project does not develop paradigms or untested methods or new untested
standards.

X

The project involves implementation of care practices and interventions that are consensus -based
or evidence-based. The project does not seek to test an intervention that is beyond current
science and experience.

X

The project is conducted by staf f where the project will take place and involves staf f who are
working at an agency that has an agreement with USF SONHP.

X

The project has no f unding f rom f ederal agencies or research-f ocused organizations and is not
receiving f unding f or implementation research.

X

The agency or clinical practice unit agrees that this is a project that will be implemented to
improve the process or delivery of care, i.e., not a personal research project that is dependent
upon the voluntary participation of colleagues, students and/ or patients.

X

If there is an intent to, or possibility of publishing your work, you and supervising f aculty and the
agency oversight committee are comf ortable with the f ollowing statement in your methods section:
“This project was undertaken as an Evidence-based change of practice project at X hospital or
agency and as such was not formally supervised by the Institutional Review Board.”

X

Answer Key:
•
•

If the answer to all of these items is “Yes”, the project can be considered an evidence-based activity that does
not meet the def inition of research. IRB review is not required. Keep a copy of this checklist in your files.
If the answer to any of these questions is “No”, you must submit for IRB approval.

*Adapted with permission of Elizabeth L. Hohmann, MD, Director and Chair, Partners Human Research Committee, Partners
Health System, Boston, MA.

No
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To qualif y as an Evidence-based Change in Practice Project, rather than a Research Project, the criteria outlined in
f ederal guidelines will be used: http://answers.hhs.gov/ohrp/categories/1569

DNP Statement of Determination
Evidence-Based Change of Practice Project Checklist Outcome
The SOD should be completed in NURS 7005 and NURS 791E/P or NURS 749/A/E

Project Title:
Utilizing Tracer Methodology to Evaluate the Ef f ectiveness of a Hospital Antibiotic Stewardship Program

X This project meets the guidelines f or an Evidence-based Change in Practice Project as outlined in the Project
Checklist (attached). Student may proceed with implementation.
☐ This project involves research with human subjects and must be submitted for IRB approval before project
activity can commence.

Comments:

Student
Last Name:

Smyth

Student
First Name:

Christine

CWID Number:

20374628

Semester/
Year:

Spring 2020
5/3/2020

Student
Signature:

Chairperson
Name:

Date:

Wanda Borges
5/6/2020

Chairperson
Signature:
DNP SOD Review
Committee
Member Name:
DNP SOD Review
Committee
Member
Signature:

Date:
Francine Seraf in-Dickson

Date:
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Appendix L
Results
Presented to Medical Director of Pharmacy
and Infection Control and Clinical
Coordinator Pharmacist (members of tracer
development team)

Shared 9/10/2020
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Appendix M
System Regional Antimicrobial Stewardship Committee Presentation
Presented to System Regional Antimicrobial
Stewardship Committee

Presented 9/21/2020
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